These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9625435)

  • 41. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
    Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
    Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
    Zwelling LA; Mitchell MJ; Satitpunwaycha P; Mayes J; Altschuler E; Hinds M; Baguley BC
    Cancer Res; 1992 Jan; 52(1):209-17. PubMed ID: 1309224
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
    Ellis AL; Nowak B; Plunkett W; Zwelling LA
    Cancer Chemother Pharmacol; 1994; 34(3):249-56. PubMed ID: 8004759
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aurintricarboxylic acid, a putative inhibitor of apoptosis, is a potent inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells.
    Benchokroun Y; Couprie J; Larsen AK
    Biochem Pharmacol; 1995 Jan; 49(3):305-13. PubMed ID: 7857317
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance.
    Baguley BC; Holdaway KM; Fray LM
    J Natl Cancer Inst; 1990 Mar; 82(5):398-402. PubMed ID: 2154584
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cyclin D3 sensitizes tumor cells to tumor necrosis factor-induced, c-Myc-dependent apoptosis.
    Jänicke RU; Lin XY; Lee FH; Porter AG
    Mol Cell Biol; 1996 Oct; 16(10):5245-53. PubMed ID: 8816437
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytotoxicity, apoptosis induction and downregulation of MDR-1 expression by the anti-topoisomerase II agent, salvicine, in multidrug-resistant tumor cells.
    Miao ZH; Tang T; Zhang YX; Zhang JS; Ding J
    Int J Cancer; 2003 Aug; 106(1):108-15. PubMed ID: 12794765
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells.
    Cheng Z; Yang N; Liang W; Yan X; Li L; Pan L
    Leuk Lymphoma; 2012 Jul; 53(7):1383-9. PubMed ID: 22185283
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transcriptional down-regulation of c-myc expression by protein synthesis-dependent and -independent pathways in a human T lymphoblastic tumor cell line.
    Bading H; Moelling K
    Cell Growth Differ; 1990 Mar; 1(3):113-7. PubMed ID: 2127692
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Transcriptional consequences of topoisomerase inhibition.
    Collins I; Weber A; Levens D
    Mol Cell Biol; 2001 Dec; 21(24):8437-51. PubMed ID: 11713279
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phorbol ester-induced down-regulation of topoisomerase II alpha mRNA in a human erythroleukemia cell line. Evidence for a post-transcriptional mechanism.
    Loflin PT; Altschuler E; Hochhauser D; Hickson ID; Zwelling LA
    Biochem Pharmacol; 1996 Oct; 52(7):1065-72. PubMed ID: 8831726
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.
    Tan KB; Mattern MR; Eng WK; McCabe FL; Johnson RK
    J Natl Cancer Inst; 1989 Nov; 81(22):1732-5. PubMed ID: 2553992
    [TBL] [Abstract][Full Text] [Related]  

  • 54. C-myc expression is down-regulated in mafosfamide-treated HL-60 cells undergoing apoptosis.
    Davidoff AN; Mendelow BV
    Anticancer Res; 1993; 13(4):1167-70. PubMed ID: 8352540
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
    de Jong S; Zijlstra JG; de Vries EG; Mulder NH
    Cancer Res; 1990 Jan; 50(2):304-9. PubMed ID: 1967222
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells.
    Bojanowski K; Lelievre S; Markovits J; Couprie J; Jacquemin-Sablon A; Larsen AK
    Proc Natl Acad Sci U S A; 1992 Apr; 89(7):3025-9. PubMed ID: 1313577
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of cathepsin proteases attenuates migration and sensitizes aggressive N-Myc amplified human neuroblastoma cells to doxorubicin.
    Gangoda L; Keerthikumar S; Fonseka P; Edgington LE; Ang CS; Ozcitti C; Bogyo M; Parker BS; Mathivanan S
    Oncotarget; 2015 May; 6(13):11175-90. PubMed ID: 25883214
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II.
    Hinds M; Deisseroth K; Mayes J; Altschuler E; Jansen R; Ledley FD; Zwelling LA
    Cancer Res; 1991 Sep; 51(17):4729-31. PubMed ID: 1651812
    [TBL] [Abstract][Full Text] [Related]  

  • 59. C-myc expression in cell lines derived from chronic myeloid leukemia.
    Gómez-Casares MT; Vaqué JP; Lemes A; Molero T; Delgado MD; León J
    Haematologica; 2004 Feb; 89(2):241-3. PubMed ID: 15003904
    [No Abstract]   [Full Text] [Related]  

  • 60. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.
    Finlay GJ; Riou JF; Baguley BC
    Eur J Cancer; 1996 Apr; 32A(4):708-14. PubMed ID: 8695277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.